Linperlisib plus chemoimmunotherapy for relapsed large B-cell lymphoma
Treatments studied
Part of Cancer, Immune system & allergy clinical trials.
This trial tests a drug called linperlisib combined with standard chemotherapy and immunotherapy for people with large B-cell lymphoma that has come back or not responded to one prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of large B-cell lymphoma (like DLBCL or high-grade B-cell lymphoma) that has come back or not responded to one prior treatment.
- You must have at least one tumor that can be measured on a scan.
- You must be at least 18 years old and be able to take care of yourself (ECOG 0-2).
- You cannot have had more than one line of cancer treatment before this trial.
- You cannot have had a stem cell transplant or a PI3K inhibitor drug before.
- You must not have active infections, autoimmune diseases, or serious heart/lung problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs for people with large b-cell lymphoma that has come back or not responded to the first treatment. It aims to see if this combination can help control the cancer and prepare for a type of cell therapy called liso-cel.
This study tests a new drug, BEBT-908, combined with rituximab for people with diffuse large B-cell lymphoma that has come back or not responded to at least one prior treatment that included a CD20 antibody. The goal is to see if this new combination works better than standard care.
This trial compares a new targeted medicine (JS203) combined with chemotherapy against a standard treatment (rituximab) with chemotherapy for people whose large B-cell lymphoma has returned or not responded. The goal is to see if the new combination works better and to offer a possible new option.
This trial tests a new drug called Linperlisib for people with a rare type of leukemia (T-cell large granular lymphocytic leukemia) that has come back or stopped responding to previous treatment. It's a possible option for patients whose blood counts are low, who have an enlarged spleen, or who have other related health problems.
This trial tests a new targeted therapy (linperlisib) combined with rituximab, an existing antibody drug, for people with a slow-growing type of non-Hodgkin lymphoma that has come back or not responded to previous treatments. The goal is to see if this combination is safe and effective in controlling the cancer.
This trial tests a combination of drugs (linperlisib, cyclophosphamide, prednisone, and thalidomide) for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments. It aims to see if this combination can help control the disease.
Hear when a new Relapsed/Refractory Large B-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.